Inbiomotion is a Barcelona-based precision medicine company, spin-out from IRB Barcelona and ICREA, dedicated to the development of single-gene biomarkers that enable oncologists to stratify patients at risk of bone metastasis and tailor adjuvant therapies accordingly.

The company’s flagship product, the MAF Test®, is designed to identify early-stage breast cancer patients whose tumours carry amplification or over-expression of the MAF gene — a key driver of bone metastasis. Through retrospective analyses of landmark clinical trials (including AZURE and NSABP-B34), Inbiomotion demonstrated that patients with MAF-negative tumours derive substantial benefit from adjuvant bisphosphonate therapies, while those with MAF-positive tumours do not — enabling more precise treatment decisions, avoiding ineffective therapies, and improving outcomes.

With commercial rollout underway in Spain, Italy, the UK and South Africa, the company is translating its scientific discovery into tangible improvements in patient care.